Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.

Menyhárt O, Giangaspero F, Győrffy B.

J Hematol Oncol. 2019 Mar 15;12(1):29. doi: 10.1186/s13045-019-0712-y. Review.

2.

Molecular Classification of Medulloblastoma.

Kijima N, Kanemura Y.

Neurol Med Chir (Tokyo). 2016 Nov 15;56(11):687-697. Epub 2016 May 26. Review.

3.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.

Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC.

Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1.

4.

Genetic grouping of medulloblastomas by representative markers in pathologic diagnosis.

Min HS, Lee JY, Kim SK, Park SH.

Transl Oncol. 2013 Jun 1;6(3):265-72. Print 2013 Jun.

5.

Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.

Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ.

Acta Neuropathol. 2011 Mar;121(3):381-96. doi: 10.1007/s00401-011-0800-8. Epub 2011 Jan 26.

6.

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.

Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL.

Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4. Review.

7.

Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.

Kaur K, Kakkar A, Kumar A, Mallick S, Julka PK, Gupta D, Suri A, Suri V, Sharma MC, Sarkar C.

Brain Pathol. 2016 May;26(3):334-43. doi: 10.1111/bpa.12293. Epub 2015 Sep 9.

PMID:
26222673
8.

Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.

Kaur K, Kakkar A, Kumar A, Purkait S, Mallick S, Suri V, Sharma MC, Julka PK, Gupta D, Suri A, Sarkar C.

J Neurooncol. 2016 Dec;130(3):423-430. Epub 2016 Aug 30.

PMID:
27576698
9.

Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas.

Harter PN, Baumgarten P, Zinke J, Schilling K, Baader S, Hartmetz AK, Schittenhelm J, Beschorner R, Liebner S, Schulte D, Plate KH, Gutwein P, Korshunov A, Pfister SM, Jones DT, Doberstein K, Mittelbronn M.

Neuropathol Appl Neurobiol. 2015 Feb;41(2):165-79. doi: 10.1111/nan.12186.

PMID:
25287489
10.

Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.

Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DT, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, von Deimling A, Scheurlen W, Kulozik AE, Clifford SC, Peter Collins V, Westermann F, Taylor MD, Lichter P, Pfister SM.

Acta Neuropathol. 2012 Apr;123(4):515-27. doi: 10.1007/s00401-011-0918-8. Epub 2011 Dec 9.

PMID:
22160402
11.

FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.

Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM.

J Clin Oncol. 2011 Oct 10;29(29):3852-61. doi: 10.1200/JCO.2011.36.2798. Epub 2011 Sep 12.

PMID:
21911727
12.

Implications of tumor location on subtypes of medulloblastoma.

Teo WY, Shen J, Su JM, Yu A, Wang J, Chow WY, Li X, Jones J, Dauser R, Whitehead W, Adesina AM, Chintagumpala M, Man TK, Lau CC.

Pediatr Blood Cancer. 2013 Sep;60(9):1408-10. doi: 10.1002/pbc.24511. Epub 2013 Mar 19.

PMID:
23512859
13.

Signaling pathway deregulation and molecular alterations across pediatric medulloblastomas.

Lhermitte B, Blandin AF, Coca A, Guerin E, Durand A, Entz-Werlé N.

Neurochirurgie. 2018 May 15. pii: S0028-3770(18)30013-4. doi: 10.1016/j.neuchi.2018.01.003. [Epub ahead of print] Review.

PMID:
29776650
14.

Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.

Kaur K, Jha P, Pathak P, Suri V, Sharma MC, Garg A, Suri A, Sarkar C.

J Neurooncol. 2019 May 18. doi: 10.1007/s11060-019-03187-y. [Epub ahead of print]

PMID:
31104222
15.

Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.

Zhang ZY, Xu J, Ren Y, Li KK, Ng HK, Mao Y, Zhong P, Yao Y, Zhou LF.

PLoS One. 2014 Jun 16;9(6):e99490. doi: 10.1371/journal.pone.0099490. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107855. PLoS One. 2014;9(8):e105742.

16.

Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.

Li Y, Jiang T, Shao L, Liu Y, Zheng C, Zhong Y, Zhang J, Chang Q.

J Neurooncol. 2016 Sep;129(3):423-431. doi: 10.1007/s11060-016-2213-y. Epub 2016 Jul 12.

PMID:
27406588
17.

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Łastowska M, Trubicka J, Niemira M, Paczkowska-Abdulsalam M, Karkucińska-Więckowska A, Kaleta M, Drogosiewicz M, Perek-Polnik M, Krętowski A, Cukrowska B, Grajkowska W, Dembowska-Bagińska B, Matyja E.

J Neurooncol. 2018 Jun;138(2):231-240. doi: 10.1007/s11060-018-2797-5. Epub 2018 Feb 9.

18.

Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.

Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E, von Bueren AO, Jones DT, Northcott PA, Kool M, Sturm D, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho BK, Kim SK, Wang KC, Eberhart CG, Fevre-Montange M, Fouladi M, French PJ, Kros M, Grajkowska WA, Gupta N, Weiss WA, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard JR, Rubin JB, Liau LM, Massimi L, Pollack IF, Shin Ra Y, Van Meir EG, Zitterbart K, Schüller U, Hill RM, Lindsey JC, Schwalbe EC, Bailey S, Ellison DW, Hawkins C, Malkin D, Clifford SC, Korshunov A, Pfister S, Taylor MD, Tabori U.

J Clin Oncol. 2013 Aug 10;31(23):2927-35. doi: 10.1200/JCO.2012.48.5052. Epub 2013 Jul 8.

19.

A simplified approach using Taqman low-density array for medulloblastoma subgrouping.

Cruzeiro GAV, Salomão KB, de Biagi CAO Jr, Baumgartner M, Sturm D, Lira RCP, de Almeida Magalhães T, Baroni Milan M, da Silva Silveira V, Saggioro FP, de Oliveira RS, Dos Santos Klinger PH, Seidinger AL, Yunes JA, de Paula Queiroz RG, Oba-Shinjo SM, Scrideli CA, Nagahashi SMK, Tone LG, Valera ET.

Acta Neuropathol Commun. 2019 Mar 4;7(1):33. doi: 10.1186/s40478-019-0681-y.

20.

Targeted treatment for sonic hedgehog-dependent medulloblastoma.

Kieran MW.

Neuro Oncol. 2014 Aug;16(8):1037-47. doi: 10.1093/neuonc/nou109. Epub 2014 Jun 20. Review.

Supplemental Content

Support Center